Takeda Pharmaceuticals announced that Kapidex (dexlansoprazole delayed-release capsules) will now be marketed under a new product trade name, Dexilant, due to reports of dispensing errors. Takeda and the FDA have received reports of dispensing errors between Kapidex and Casodex (bicalutamide tablets, from AstraZeneca) and have determined a name change would be the best way to minimize future medication errors. The formulation, indication, and approved dosages of Dexilant will remain the same as Kapidex. Markings on the capsules and the capsule appearance will be identical to capsules marketed under the Kapidex trade name.
Kapidex, now Dexilant, is indicated for the treatment of erosive esophagitis (EE) and heartburn related to non- erosive gastroesophageal reflux disease (GERD) as well as the maintenance of healing of EE.
For more information call (877) TAKEDA-7 or visit www.tpna.com.